Are you a client?
Sign in to view the full news archive.
The Royal Marsden NHS Foundation Trust has signed a new partnership with NTT DATA and CARPL.ai for the UK's first large-scale AI-powered radiology platform for oncology research, representing a step forward for the deployment of AI in British healthcare.
This three-year, National Institute for Health and Care Research (NIHR)-funded initiative demonstrates the maturation of AI-driven healthcare solutions beyond pilot programs. By targeting multiple cancer types—sarcoma, lung, breast, brain, and prostate—the platform is looking to address substantial clinical needs while building an evidence base for AI efficacy in real-world settings.
The solution is built on Dell/NVIDIA infrastructure within NHS security frameworks and addresses key healthcare AI challenges: data privacy, computational scalability, and regulatory compliance. CARPL.ai's MLOps platform enables both algorithm testing and performance monitoring—essential capabilities for clinical translation.
The partnership is combining established healthcare providers, enterprise technology integrators, and specialised AI platforms and likely previews an attractive model for healthcare AI adoption. The emphasis on research-grade validation and NHS integration suggests a pathway from experimental AI to mainstream clinical deployment.
The potential for AI in healthcare is without doubt, but most projects remain as small-scale studies. Given the prominence of the Royal Marsden as one of the world’s top cancer research centres, success here could accelerate similar partnerships across other NHS trusts and internationally. The initiative's focus on developing actionable insights from real clinical data, rather than theoretical AI capabilities, positions it to generate the evidence base necessary for broader healthcare AI adoption.
Posted by: Marc Hardwick at 08:33
Tags:
health
AI
partnership